Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02441075 · ClinicalTrials.gov registry record · NA

70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014

A NA study, sponsored by Nationwide Children's Hospital.

Completed
Registry status
NA
Development phase
13
Enrollment target

NCT02441075 is a NA study that has completed, run by Nationwide Children's Hospital. The registered enrollment target is 13 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02441075, a NA study, has completed, sponsored by Nationwide Children's Hospital.

COMPLETED
Registry status
NA
Development phase
13 participants
Enrollment target

Study Summary

This is for a study for patients that will be undergoing hematopoietic stem cell transplant (HSCT). For HSCT, patients will need a double lumen central venous line (CVL). One of the most common complications after an HSCT is Graft Versus Host Disease (GVHD).Tacrolimus or Cyclosporine along with methotrexate are used together in order to prevent GVHD. Normally these medications are given via the white lumen and blood is drawn via the unexposed red lumen to check the blood level of these medications. If these drugs are accidentally given via the wrong lumen (line) it could cause blood levels to be falsely high. This error could lead to the patient having to have peripheral blood draws that cause pain. The investigators are proposing adding an ethanol lock to your lumens (lines) to see if this would help clean the lines therefore preventing errors in blood tests and blood draws. An ethanol lock is a 70% alcohol which is injected into the CVL lumen and stays within the CVL as the CVL is capped.

Interventions

  • OTHER 70% Ethanol

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2014-05
Est. Completion 2016-01
Phase NA

Sponsor

Nationwide Children's Hospital

188 total trials

What the Registry Record Tells You About NCT02441075

The ClinicalTrials.gov registry entry for NCT02441075 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which 70% Ethanol is the first listed.

NCT02441075 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02441075 about?

NCT02441075 is a clinical study titled "70% Ethanol for Decontamination of CVL Exposed to Calcineurine Inhibitors Version 1.0, 1/9/2014". This is for a study for patients that will be undergoing hematopoietic stem cell transplant (HSCT). For HSCT, patients will need a double lumen central venous line (CVL). One of the most common complications after an HSCT is Graft Versus Host Disease (GVHD).Tacrolimus or Cyclosporine along with meth...

What is the current status of trial NCT02441075?

This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2014-05. Estimated completion is 2016-01.

What interventions are being tested in trial NCT02441075?

The interventions under investigation include: 70% Ethanol (OTHER).

Who is sponsoring clinical trial NCT02441075?

This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.